FDA Peptide Regulation and HHS Policy Holt Law BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved peptides #fda #longevity #glp1 #precisionmedicine #compounding Katherine Erickson The reason peptide access is changing comes down to two regulatory categories most patients don't know exist: 503A and 503B. 503A = traditional compounding pharmacies. State licensed, patient specific prescriptions. 503B = FDA registered outsourcing Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg #